The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-complex MPGN. This trial builds on prior upstream complement strategies and strengthens the case for disease-targeted therapy in C3G.

Check out the VA Dr. Akshaya Jayachandran and don´t forget to join #NephJC on bluesky.